Trial Profile
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms VOCAL
- Sponsors Vertex Pharmaceuticals
- 12 Nov 2020 Status changed from active, no longer recruiting to completed.
- 24 Sep 2020 According to a Vertex Pharmaceuticals media release, data from this study will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020.
- 07 Jun 2018 According to the Vertex Pharmaceuticals media release, data from this trial were presented at the 41st European Cystic Fibrosis Conference 2018.